Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms …

B Williams, TM MacDonald, SV Morant… - The lancet Diabetes & …, 2018 - thelancet.com
Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced
blood pressure substantially more than conventional antihypertensive drugs. We did three …

[HTML][HTML] Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised …

B Williams, TM MacDonald, S Morant, DJ Webb… - The Lancet, 2015 - thelancet.com
Background Optimal drug treatment for patients with resistant hypertension is undefined. We
aimed to test the hypotheses that resistant hypertension is most often caused by excessive …

Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment)

EM Krieger, LF Drager, DMA Giorgi, AC Pereira… - …, 2018 - Am Heart Assoc
The aim of this study is to compare spironolactone versus clonidine as the fourth drug in
patients with resistant hypertension in a multicenter, randomized trial. Medical therapy …

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double …

R Agarwal, P Rossignol, A Romero, D Garza, MR Mayo… - The Lancet, 2019 - thelancet.com
Background Spironolactone is effective at reducing blood pressure in patients with
uncontrolled resistant hypertension. However, the use of spironolactone in patients with …

Effect of spironolactone on blood pressure in subjects with resistant hypertension

N Chapman, J Dobson, S Wilson, B Dahlof… - …, 2007 - Am Heart Assoc
Spironolactone is recommended as fourth-line therapy for essential hypertension despite
few supporting data for this indication. We evaluated the effect among 1411 participants in …

Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial

CS Oxlund, JE Henriksen, L Tarnow… - Journal of …, 2013 - journals.lww.com
Background: The increased risk of cardiovascular morbidity and mortality associated with
arterial hypertension is particularly pronounced in patients with type 2 diabetes mellitus …

Efficacy of spironolactone therapy in patients with true resistant hypertension

F de Souza, E Muxfeldt, R Fiszman, G Salles - Hypertension, 2010 - Am Heart Assoc
The role of spironolactone in resistant hypertension management is unclear. The aim of this
prospective trial was to evaluate the antihypertensive effect of spironolactone in patients with …

Low-dose spironolactone in the management of resistant hypertension: a surveillance study

DA Lane, S Shah, DG Beevers - Journal of hypertension, 2007 - journals.lww.com
Methods We have conducted an open observational study of the use of spironolactone 25–
50 mg in the management of patients with resistant hypertension. This drug was …

A meta-analysis of add-on use of spironolactone in patients with resistant hypertension

D Zhao, H Liu, P Dong, J Zhao - International journal of cardiology, 2017 - Elsevier
Objective The efficacy of add-on use of spironolactone in patients with resistant
hypertension has been investigated in several small studies. We performed this meta …

Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials

C Wang, B Xiong, J Huang - Heart, Lung and Circulation, 2016 - Elsevier
Background The treatment of resistant hypertension (RH) is challenging. Several
observational studies have suggested that the addition of spironolactone to triple-drug …